Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

19.19 USD -0.01 (-0.05%)
Official Closing Price Updated: 6:47 PM EST, Mar 2, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Alkermes Plc

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Resources for Those Recovering From or Struggling With Alcohol Use Disorder
Tags Mental Health Responsible Production & Consumption Disease Awareness
From 3BL Media: Corporate Social Responsibility, Energy and Health News
A Meaningful Difference for Cancer Patients and Loved Ones
Tags Employee Engagement Corporate Social Responsibility Disease Awareness
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET
Alkermes plc (Nasdaq: ALKS) announces that the conference call to discuss the company's third quarter financial results is rescheduled due to technical difficulties impacting the conference call... 
From PR Newswire
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
- Company Reports Third Quarter Revenues of $265.0 Million, GAAP Net Loss per Share of $0.00 and Basic and Diluted Non-GAAP Earnings per Share of $0.26 - 
From PR Newswire
Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors
Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors 
From Business Wire News Releases
Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Thursday, Oct. 29, 2020 to discuss the company's third quarter 2020 financial... 
From PR Newswire
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
Alkermes plc (Nasdaq: ALKS) today announced positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory... 
From PR Newswire
Trading in Alkermes Ordinary Shares Halted Today
-- FDA Advisory Committee to Review New Drug Application for ALKS 3831 for the Treatment of Adults with Schizophrenia or Bipolar I Disorder -- 
From PR Newswire
Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the Oct. 9, 2020 joint meeting of the Psychopharmacologic... 
From PR Newswire
Physical Distancing During COVID-19 Doesn't Have To Mean Feeling Alone
Tags Public Health Improving Healthcare Access Health & Healthcare
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Recovery Month at Alkermes
Tags Responsible Production & Consumption Disease Awareness Mental Health
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Shares Mental Health Resources During National Suicide Prevention Month
Tags suicide prevention month Social Impact & Volunteering Alkermes
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Thinking about trading options or stock in Apple, Dave & Buster's, Alkermes, American Airlines, or Arch Resources?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, PLAY, ALKS, AAL, and ARCH. 
From PR Newswire
Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress
- Data Provide Evidence of Clinical Benefit and Tolerability of ALKS 4230 as Monotherapy in Melanoma and in Combination With Pembrolizumab in Multiple Tumor Types - 
From PR Newswire
Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience
Tags Healthcare Innovation Events, Media & Communications Pharma News, Research & Solutions
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience
-- New Outcomes Research Analyzed Patterns of Weight Gain and Treatment Interruptions Associated With the Use of Second-Generation Oral Antipsychotics in Patients With Schizophrenia or Bipolar I... 
From PR Newswire
Alkermes to Take Part in Cantor Virtual Global Healthcare Conference
Alkermes plc (Nasdaq: ALKS) announced today that that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday,... 
From PR Newswire
Alkermes to Present New Data on Investigational Immuno-Oncology Candidate, ALKS 4230, at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress
Company to Host Investor Webcast at 8:30 a.m. ET on Friday, Sept. 18, 2020 
From PR Newswire
International Overdose Awareness Day
Tags Social Impact & Volunteering Life Science Responsible Production & Consumption
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Sunscreen Tips for Summer
Tags Health & Healthcare American Cancer Society Public Health
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Virtual FDA Advisory Committee Meeting to Review New Drug Application for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020
Alkermes plc (Nasdaq: ALKS) today announced that a joint meeting of the U.S. Food and Drug Administration's (FDA) Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management... 
From PR Newswire
Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors
Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-3, a new phase 2 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy on the tumor microenvironment of... 
From PR Newswire
American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia
Alkermes plc (Nasdaq: ALKS) today announced the publication of results from the phase 3 ENLIGHTEN-2 clinical trial of ALKS 3831 (olanzapine/samidorphan) in the peer-reviewed publication, American... 
From PR Newswire
NetworkNewsBreaks – Alkermes plc (NASDAQ: ALKS) Featured in Mizuho Securities Research Report
From InvestorBrandNetwork
Alkermes Releases Third Annual Corporate Responsibility Report
Tags CSR Reports Responsible Production & Consumption Governance
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
-- Company Reports Second Quarter Revenues of $247.5 Million, GAAP Net Loss per Share of $0.19 and Diluted Non-GAAP Earnings per Share of $0.06 -- 
From PR Newswire
Alkermes to Host Conference Call to Discuss Second Quarter 2020 Financial Results
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 29, 2020 to discuss the company's second quarter 2020 financial... 
From PR Newswire
Alkermes: Supporting Our Patients During COVID-19
Tags Public Health Schizophrenia Pharma News, Research & Solutions
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Melanoma: Risk Factors and Prevention
Tags skin cancer NASDAQ:ALKS Health & Healthcare
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Cancer Immunotherapy Awareness Month™ at Alkermes
Tags Health & Healthcare Improving Healthcare Access SITC
From 3BL Media: Corporate Social Responsibility, Energy and Health News
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.